# The Effects of Soy Protein–Rich Meals on Muscle Health of Older Adults Are Linked to Gut Microbiome Modifications

**Authors:** Xiaorong Wu, Kevin Junliang Lim, Yiwei Ma, Jie Gu, Yuanrong Jiang, Liying Zhu, Yanqiu Chen, Jianqing Sun

PMC · DOI: 10.1002/jcsm.70212 · Journal of Cachexia, Sarcopenia and Muscle · 2026-01-25

## TL;DR

A soy protein-rich diet may improve muscle health in older adults by changing gut bacteria, suggesting a link between gut health and muscle function.

## Contribution

This study shows that soy protein improves muscle health in older adults by modifying gut microbiota, supporting the gut–muscle axis hypothesis.

## Key findings

- Participants on a soy protein-rich diet preserved calf circumference, while the control group's decreased.
- The intervention increased SCFA-producing bacteria like Roseburia faecis and decreased harmful species like Alistipes putredinis.
- Functional analysis showed reduced inflammatory pathways and increased vitamin biosynthesis in the intervention group.

## Abstract

Sarcopenia is characterized by accelerated muscle mass and function loss in older adults. The role of nutritional interventions in sarcopenia is uncertain. This study investigates whether a soy protein–rich diet can enhance muscle health in older adults via gut microbiota changes.

A 12‐week randomized controlled trial was conducted with 84 older adults from a long‐term care facility. Participants in the intervention group consumed three daily meals containing 10 g of soy protein (totalling 30 g/day), while the control group maintained their usual diets. Faecal samples from 53 participants were collected at Weeks 0, 6 and 12. We assessed changes in muscle function, gut microbiota composition and faecal short‐chain fatty acids (SCFA).

The intervention group showed preserved calf circumference, while the control group experienced a decrease (W12‐W0: Intervention, 0.56 ± 0.22 cm; Control, −0.91 ± 0.26 cm, p
(interaction) < 0.001). Metagenomic analysis revealed significant alterations in gut microbiota among intervention participants who showed improvement in muscle performance parameters. The intervention increased SCFA‐producing bacteria (
Roseburia faecis
, Intervention: 0.42 ± 0.21%, Control: −0.06 ± 0.16, p
(interaction) < 0.05; 
Agathobaculum butyriciproducens
, Intervention: 0.02 ± 0.007%, p
(time) < 0.01, Control: −0.04 ± 0.01) and decreased species associated with poorer muscle outcomes (
Alistipes putredinis
, Intervention: −0.88 ± 0.40%, Control: 0.62 ± 0.63, p
(interaction) < 0.05; Eubacterium_sp_CAG_38, Intervention: −0.64 ± 0.28%, Control: 0.10 ± 0.22, p
(interaction) < 0.05). Functional pathway analysis showed enrichment of anaerobic amino acid degradation pathways and vitamin biosynthesis, with depletion of inflammatory pathways, particularly lipopolysaccharide biosynthesis. Microbiome phenotype prediction revealed a decrease in aerobic bacteria abundance in the intervention group (W12‐W0, Intervention: −0.004 ± 0.002; Control: 0.001 ± 0.001, p
(interaction) < 0.05). Interaction (group × time) for SCFA was not statistically significant; within‐group increases at Week 6 were observed in only the intervention group (butyric acid, Intervention: 0.74 ± 0.34 mg/g, p
(time) < 0.05, Control: 0.12 ± 0.43 mg/g; isobutyric acid, Intervention: 0.14 ± 0.08 mg/g, p
(time) < 0.05, Control: 0.08 ± 0.10 mg/g; isovaleric acid, Intervention: 0.27 ± 0.14 mg/g, p
(time) < 0.05; Control: 0.16 ± 0.20 mg/g), with partial reversal by Week 12. These changes, positively correlated with improved muscle function parameters, suggest intervention benefits on gut health and muscle function.

A soy protein–rich intervention improved muscle health in older adults through beneficial gut microbiota. These findings support the gut–muscle axis hypothesis and suggest dietary soy protein may alleviate sarcopenia by promoting a healthier gut microbiome.

## Full-text entities

- **Genes:** SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, CRP (C-reactive protein) [NCBI Gene 527553], IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, LOC517016 (interleukin 6 (interferon, beta 2)) [NCBI Gene 517016] {aka IF1DA6}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, IL6 (interleukin 6) [NCBI Gene 280826], IGF1 (insulin like growth factor 1) [NCBI Gene 281239] {aka IGF-1, IGF-I}, NR1H4 (nuclear receptor subfamily 1 group H member 4) [NCBI Gene 9971] {aka BAR, FXR, HRR-1, HRR1, PFIC5, RIP14}
- **Diseases:** muscle pain (MESH:D063806), vomiting (MESH:D014839), Sarcopenia (MESH:D055948), stroke (MESH:D020521), alcoholism (MESH:D000437), mobility impairment (MESH:D014086), frailty (MESH:D000073496), obese (MESH:D009765), muscle mass and (MESH:C536030), muscle atrophy (MESH:D009133), NMJ (MESH:D020511), inflammatory bowel disease (MESH:D015212), loss (MESH:D016388), cramps (MESH:D009120), SMI (MESH:D005207), weight loss (MESH:D015431), overweight (MESH:D050177), heart, liver and kidney failure (MESH:D006333), cognitive impairment (MESH:D003072), malnutrition (MESH:D044342), atherosclerosis (MESH:D050197), gout (MESH:D006073), lactose intolerance (MESH:D007787), gastrointestinal obstruction (MESH:D005767), nausea (MESH:D009325), medical or psychological diseases (MESH:D000067073), autism (MESH:D001321), Inflammatory (MESH:D007249), diarrhoea (MESH:D003967), allergies (MESH:D004342)
- **Chemicals:** formic acid (MESH:C030544), isobutyric acid (MESH:C020380), amino acid (MESH:D000596), agarose (MESH:D012685), colanic acid (MESH:C004275), butyrate (MESH:D002087), TCA (MESH:D014238), fatty acids (MESH:D005227), glutamate (MESH:D018698), O-antigen (MESH:D019081), 4-methyl valeric acid (MESH:C034527), SCFA (MESH:D005232), sulfur (MESH:D013455), pectin (MESH:D010368), BCAAs (MESH:D000597), Biotin (MESH:D001710), beta-(1,4)-mannan (MESH:C081692), ZymoBIOMICS (-), methionine (MESH:D008715), Butyric acid (MESH:D020148), cysteine (MESH:D003545), lysine (MESH:D008239), carbohydrate (MESH:D002241), FT (MESH:D005641), arginine (MESH:D001120), starch (MESH:D013213), acetic (MESH:D019342), ATP (MESH:D000255), menaquinones (MESH:D024482), Helium (MESH:D006371), glycogen (MESH:D006003), acetate (MESH:D000085), essential amino acids (MESH:D000601), ethanol (MESH:D000431), polyunsaturated fatty acids (MESH:D005231), 25-hydroxyvitamin D (MESH:C104450), GDP-mannose (MESH:D006155), hydrogen (MESH:D006859), vitamin D (MESH:D014807), LPS (MESH:D008070), Water (MESH:D014867), GC (MESH:C057580), isovaleric acid (MESH:C008216)
- **Species:** Ganoderma (genus) [taxon 5314], Monoglobus pectinilyticus (species) [taxon 1981510], Candidatus Amulumruptor (genus) [taxon 2510710], Eubacterium (genus) [taxon 1730], Mus musculus (house mouse, species) [taxon 10090], Roseburia faecis (species) [taxon 301302], Alistipes putredinis (species) [taxon 28117], Dorea formicigenerans (species) [taxon 39486], Bos taurus (bovine, species) [taxon 9913], Lachnoclostridium (genus) [taxon 1506553], Lactobacillus (genus) [taxon 1578], Parabacteroides distasonis (species) [taxon 823], gut metagenome (species) [taxon 749906], Agathobaculum butyriciproducens (species) [taxon 1628085], Parabacteroides merdae (species) [taxon 46503], Glycine max (soybean, species) [taxon 3847], Ruminococcus (genus) [taxon 1263], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12833501/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12833501/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12833501/full.md

---
Source: https://tomesphere.com/paper/PMC12833501